200 mg of Hydroxychloroquine orally three times daily for 10 days plus 500 mg of Nitazoxanide orally twice daily for 6 days

Standard care delivered in the COVID-19 isolation hospitals.

COVID-19

Both hydroxychloroquine & nitazoxanide will be administered orally to participating patients

Hydroxychloroquine plus Nitazoxanide

Oxygen administered via ventilator. In addition, antipyretic "paracetamol" may be added if necessary

Standard care

Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19

Clinical Trial Evaluating Safety and Efficacy of Hydroxychloroquine and Nitazoxanide Combination as Adjuvant Therapy in Covid-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope

improved breaths per minute for the patients

Serum iron in microgram/dL of the patients

Serum ferritinin microgram/L of the patients

International normalized ratio "INR" for prothrombin time of 2

CBC for lymphocyte count in cells/microliter

Mortality rate [number of dead patients/total number of treated patients]

Prof. Dr. Kamal Mohammed Okasha

Vice-President of Postgraduate Studies and Research Affairs

Tanta University

a double blind randomized controlled parallel study

30 Patients will be treated with combined DFP and deferasirox.

Patients will be treated for 6 days with a combination of deferoxamine and DFP

Beta-thalassemia Major

Sickle Cell Disease

Iron Hemosiderosis

Drug: Ferriprox It will be given orally in the morning Other Name: DFP Initial dose 25/mg/kg 3 times/d (better tolerated if started and then built up over 4 weeks).
Dose may be increased up to 100mg/kg/day guided by serum ferritin. Agranulocytosis risk 1-2%. Monitor TLC and granulocytic count / 2weeks. Patients need to be continually educated about this risk, know that they must stop DFP if they have a fever or infection.
Drug: Deferasirox will be orally administered at a dose of 20 mg/kg once daily at evening for 5 days.
Other Name: ICL670

DFP (ferriprox) and deferasirox (ICL 670)

Drug: Deferoxamine It will be administered subcutaneously over 8 hours for 5 days at a dose of 40 mg/kg.
Other Name: Desferal, DFO Drug: DFP DFP: will be orally administered at a dose of 75mg/kg orally in 3 divided doses for 7 days

DFP, DFO

Pediatric Hematology clinic, Ain Shams University

Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload

A Prospective Randomized Comparative Study of Efficacy and Safety of Combined Deferiprone (DFP) and Deferasirox Versus DFP and Desferrioxamine (DFO) Therapy in Diseases With Severe Iron Overload

• The primary outcome measure is to measure the change in serum ferritin level from baseline in the 2 combination therapy.

• The secondary outcome measure is to determine the number of patients who will develop adverse reactions upon administering the drugs in combination.

Mohsen Saleh Elalfy

professour of pediatrics

Ain Shams University

non-randomized open-label uncontrolled phase II trial

Non-Small Cell Lung Cancer

Brain Metastasis

gefitinib 250mg qd until disease progression or unacceptable toxicity.

gefitinib

Efficacy of Gefitinib for Brain Metastasis of Non-Small Cell Lung Cancer

A Phase II Study of Gefitinib in Benefited Patients With Asymptomatic Brain Metastasis Advanced Non-Small Cell Lung Cancer by Chemotherapy

Yilong,Wu

Guangdong Provincial People's Hospital

Digibind treatment plus standard of care
Anti-digoxin antibody (FAB fragment): intravenous administered, dose based on weight (assuming 4ng/mL EDLF concentration). Dose every 6 hours x 48 hours.

Digoxin Immune Fab

Placebo

Total

Sex: Female, Male

Race (NIH/OMB)

change from baseline in creatinine clearance measured at 24 to 48 hours, comparing patients who received placebo with those who received digoxin immune fab

Change in Creatinine Clearance

Overall Study

Suzanne Ward Pharm D

Pre-eclampsia

intravenous administered, dose based on weight (assuming 4ng/mL EDLF concentration). Dose every 6 hours x 48 hours.

Anti-digoxin antibody (FAB fragment)

sodium chloride

University of South Alabama

Phoenix Perinatal Associates

Winnie Palmer Hospital

Department of Obstetrics and Gynecology, Louisiana State University Health Sciences Center, PO Box 33932, 1501 Kings Highway

St Mary's Health Center

Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 634, PO Box 250619

Department of OB-GYN, Division of Maternal Fetal Medicine, University of Texas Medical Branch, 301 University Boulevard

St Mark's Hospital

Efficacy Study of Digibind for Treatment of Severe Preeclampsia

A Parallel, Double-blind, Placebo Controlled, Randomized Comparison of an Anti-digoxin Antibody (Digibind) Versus Placebo for the Treatment of Antepartum Patients With Severe Preeclampsia

digoxin/seizures

Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19

Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload

Efficacy of Gefitinib for Brain Metastasis of Non-Small Cell Lung Cancer

Efficacy Study of Digibind for Treatment of Severe Preeclampsia

Bilim tarafından desteklenen en eksiksiz şifalı otlar veritabanı